Tel: 514–461–1300


Get the latest on MHICC through recent headlines, feature stories and news. Stay up-to-date on the latest news and information from MHICC.

  • Date Published:2021-02-19

    A natural product to fight symptoms related to COVID-19

    The Montreal Heart Institute (MHI) is launching a new clinical trial to evaluate the effect of hesperidin on symptoms related to COVID-19. This flavonoid naturally found in citrus fruits has distinct properties that may reduce the entry and replication of the SARS-CoV2 virus in the body along with the modulation of inflammatory mediators, thus potentially reducing symptoms and prevent complications from the disease.

    Open Attachment»

  • Date Published:2021-01-26

    Positive results from COLCORONA trial show that colchicine is the only effective oral medication for treating non-hospitalized patients MONTREAL, January 22, 2021 – The Montreal Heart Institute (MHI) announced today that the COLCORONA clinical trial has provided clinically persuasive results of colchicine’s efficacy to treat COVID-19. The study results have shown that colchicine has reduced by 21% the risk of death or hospitalizations in patients with COVID-19 compared to placebo.

    Open Attachment»

  • Date Published:2015-10-29

    Un médecin spécialiste montréalais a reçu, lundi à  Toronto, le prix du conférencier émérite en sciences cardiovasculaires des Instituts de recherche en santé du Canada (IRSC), à  l'occasion du Congrès canadien sur la santé cardiovasculaire. Le Dr Jean-Claude Tardif est directeur du Centre de recherche famille Desmarais de l'Institut de cardiologie de Montréal, professeur de médecine à  l'Université de Montréal et titulaire de la Chaire de recherche du Canada en médecine translationnelle et personnalisée.

    Open Attachment»

  • Date Published:2015-08-31

    Le Directeur général de l'Institut de Cardiologie de Montréal (ICM), Dr Denis Roy, tient à  souligner la nomination du Dr Jean-Claude Tardif, cardiologue, au sein de l'Ordre du Canada, et le félicite de cet honneur en reconnaissance de son apport aux soins de santé, et de sa contribution à  l'avancement de la recherche en cardiologie.
    Le Dr Tardif est directeur du Centre de recherche de l'ICM, le plus important centre de recherche en cardiologie au Québec et au Canada. Il a aussi fondé le Centre de coordination des innovations en santé de Montréal (MHICC), aujourd'hui un des plus importants centres de coordination d'essais cliniques en Amérique du Nord. Le Dr Tardif est également détenteur de la Chaire de recherche au Canada en médecine translationnelle et personnalisée, et titulaire de la Chaire Pfizer en athérosclérose de l'Université de Montréal.

    Open Attachment»

  • Date Published:2014-12-10

    Background: Pulmonary vein (PV) isolation (PVI) has emerged as an effective therapy for paroxysmal atrial fibrillation (AF). However, AF recurs in up to 50% of patients, generally because of recovery of PV conduction. Adenosine given during the initial procedure may reveal dormant PV conduction, thereby identifying the need for additional ablation, leading to improved outcomes. The Adenosine Following Pulmonary Vein Isolation to Target Dormant Conduction Elimination (ADVICE) study is a prospective multicentre randomized trial assessing the impact of adenosine-guided PVI in preventing AF recurrences. Methods: Patients undergoing a first PVI procedure for paroxysmal AF will be recruited. After standard PVI is completed, all patients will receive intravenous adenosine in an attempt to unmask dormant conduction. If dormant conduction is elicited, patients will be randomized to no further ablation (control group) or additional adenosine-guided ablation until dormant conduction is abolished. If no dormant conduction is revealed, randomly selected patients will be followed in a registry. The primary outcome is time to first documented symptomatic AF recurrence. Assuming that dormant conduction is present in 50% of patients post PVI and symptomatic AF recurs in 45% of controls, 244 patients with dormant conduction will be required to obtain  90% power to detect a difference of 20%. Thus, a total of 488 patients will be enrolled and followed for 12 months. Conclusion: The ADVICE trial will assess whether a PVI strategy incorporating elimination of dormant conduction unmasked by intravenous adenosine will decrease the rate of recurrent symptomatic AF compared with standard PVI.

    Open Attachment»